Governments tighten oversight of AI medical devices

Governments in the UK, US and EU are moving to tighten regulation of AI used in healthcare, focusing on approval standards, postmarket monitoring and accountability. The UK’s National Commission into the Regulation of AI in Healthcare proposed 44 recommendations after gathering input from over 12,000 stakeholders, calling for a lifecycle-based, risk-proportionate system for AI-powered medical devices.

The UK plan would replace a one-time approval model with staged “L-plate” authorizations, where systems operate under supervision before full clearance. It also calls for continuous monitoring of real-world performance, public access to safety data and stronger enforcement powers for the Medicines and Healthcare products Regulatory Agency.

In the US, the Food and Drug Administration released a discussion paper on August 18, 2026 for generative AI-enabled medical devices, covering risk assessment, premarket evaluation and postmarket monitoring. Comments are due by October 19, 2026. The FDA has not authorized any generative AI-enabled medical device, though it granted breakthrough designation to one patient-facing clinical application involving generative AI in March 2026.

The EU AI Act will treat many medical AI systems as high-risk, bringing obligations for transparency, data governance and human oversight. Enforcement of full high-risk obligations is scheduled for December 2027 for standalone AI applications and August 2028 for AI embedded in specific devices.